Skip to main content

OrbiMed — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

289
Companies
$24.3B
Total invested
$109.6M
Avg. check
19
Industries
Biotechnology 20Health Care 17Therapeutics 12Medical 7Pharmaceutical 6Life Science 5+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 289
ReCode Therapeutics
September 2025

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.

Biopharma · Dallas$29.4M Debt Financing
Synlogic
September 2023

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.

Biotechnology · Cambridge$21.0M Post-IPO Equity
ACELYRIN
September 2022

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Biopharma · Los Angeles$300.0M Series C
XinThera
August 2021

XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.

Biotechnology · San Diego$50.0M Series B
Neurogastrx
August 2021

A private biopharmaceutical company .

Biotechnology · Woburn$60.0M Series B
scPharmaceuticals
August 2024

ScPharmaceuticals is a biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.

Biotechnology · Lexington$125.0M Post-IPO Debt
GentiBio
August 2021

GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.

Biotechnology · Seattle$157.0M Series A
Fore Biotherapeutics
July 2026

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$67.4M Series D
NeRRe Therapeutics
July 2021

NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.

Biotechnology · Stevenage$27.6M Series B
Brenig Therapeutics
July 2024

Brenig Therapeutics develops therapies for neurodegenerative disorders.

Health Care · Dover$65.0M Series A
DarioHealth
July 2026

DarioHealth is a digital therapeutics company engaged in the development and commercialization of patented and proprietary technology.

Health Care · New York$23.5M Post-IPO Equity
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant
DELFI Diagnostics
July 2022

DELFI's AI platform uses whole-genome sequencing to detect cancer-associated cfDNA fragmentation patterns in the blood.

Artificial Intelligence (AI) · Palo Alto$225.0M Series B
Belenos Biosciences
July 2024

Belenos Biosciences is a company.

New York$48.0M Seed
Scorpion Therapeutics
July 2024

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

Biotechnology · Boston$150.0M Series C
Asceneuron
July 2024

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

Biotechnology · Lausanne$100.0M Series C
TytoCare
July 2026

TytoCare is a telehealth platform for AI-powered and on-demand remote medical examinations.

Health Care · New York$25.0M Venture - Series Unknown
Q32 Bio
July 2026

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Biotechnology · Cambridge$200.0M Post-IPO Equity
Turnstone Biologics
July 2021

Turnstone Biologics is a privately-held clinical stage biotech company.

Biotechnology · La Jolla$80.0M Series D
Imara
July 2021

Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.

Biopharma · Cambridge$50.0M Post-IPO Equity
Erasca
July 2026

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Biotechnology · San Diego$632.5M Post-IPO Equity
Renasant Bio
July 2025

Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.

Biotechnology · Berkeley$54.5M Seed
Rhythm Pharmaceuticals
July 2025

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics

Biotechnology · Boston$175.0M Post-IPO Equity
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B

Where OrbiMed invests

Biotechnology20
Health Care17
Therapeutics12
Medical7
Pharmaceutical6
Life Science5

About OrbiMed's portfolio

How many companies has OrbiMed invested in?

OrbiMed has invested in 289 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does OrbiMed invest in?

OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 19 different industry categories.

What is OrbiMed's largest investment?

Among tracked funding rounds, Erasca received $632.5M in a Post-IPO Equity round. OrbiMed's total known invested capital is $24.3B.

What is the average investment size for OrbiMed?

OrbiMed's average investment size is $109.6M across its portfolio of 289 companies.

What are OrbiMed's most recent investments?

Recent OrbiMed portfolio additions include ReCode Therapeutics, Synlogic, ACELYRIN, XinThera, Neurogastrx. These companies were founded in 2020 or later.

Reach the founders behind these 289 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →